Trius Therapeutics Inc
- Headquarters
- San Diego, CA
- Founded
- 2007
- Latest Form D
- $30.2M, Jun 2011
- Total capital
- $82.9M
- Federal grants
- $33.6M
- 11 awards · 2002–2013
- Private capital raised
- $49.3M
- 2 Form D · last Jun 2011
- 185 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 12 pending · first 2013
Capital timeline
Latest events
- Federal grantHealth and Human S · N01 · A Novel Drug for Biodefense and Emerging Infectious Diseases$3.6M
- Private capital raisedForm D · SEC · 2nd filing$30.2M
- Private capital raisedForm D · SEC · 1st filing$19.2M
- Federal grantHealth and Human S · N01 · Development of Novel Agents for Gram-Negative Biodefense Pathogens$11.5M
- Federal grantHealth and Human S · N01 · Development of Novel Agents for Gram-Negative Biodefense Pathogens$5.5M
- Federal grantHealth and Human S · N01 · Development of Novel Agents for Gram-Negative Biodefense Pathogens$8.7M
- Federal grantHealth and Human S · R03 · Identification of Target-Specific Antimicrobials$2K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase I · Novel Bacterial Cell Wall Biosynthesis Inhibitors for Biodefense Therapeutics$586K
- Federal grantHealth and Human S · Phase I · Novel Bacterial Cell Wall Biosynthesis Inhibitors for Biodefense Therapeutics$619K
- Federal grantHealth and Human S · Phase I · Novel Antibacterial Designed Multiple-Target Ligands$299K
- Federal grantHealth and Human S · Phase II · Target and antibiotic discovery in Bacillus anthracis$753K
- Federal grantHealth and Human S · Phase II · Target and antibiotic discovery in Bacillus anthracis$1.1M
- Federal grantHealth and Human S · Phase II · Target and antibiotic discovery in Bacillus anthracis$953K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
88months
from Trius Therapeutics Inc’s first federal award to its first private round.
- First federal award · Jul 2002
- Health and Human S · $953K
- First Form D · Nov 2009
- $19.2M · 1st Form D
- Awards before first raise
- 10 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Kenneth G. BartizalResearcherExecutive OfficerLinked by 1 patent
- John FinnResearcherExecutive OfficerLinked by $3.9M in grants as PI
- Brenden R. O'LearyDirectorNamed in SEC Form D filings
- Brian G. AtwoodDirectorNamed in SEC Form D filings
- David S. KabakoffDirectorNamed in SEC Form D filings
- Jeffrey SteinExecutive Officer, DirectorNamed in SEC Form D filings
Show all 15 people
- John P. SchmidExecutive OfficerNamed in SEC Form D filings
- Karin S. EasthamDirectorNamed in SEC Form D filings
- Michael R. MorneauExecutive OfficerNamed in SEC Form D filings
- Michael G. PowellDirectorNamed in SEC Form D filings
- Nina G. KjellsonDirectorNamed in SEC Form D filings
- Paul TruexDirectorNamed in SEC Form D filings
- Philippe S. ProkocimerExecutive OfficerNamed in SEC Form D filings
- Risa P. StackDirectorNamed in SEC Form D filings
- Theodore R. SchroederDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 13- PendingOxazolidinone Containing Dimer Compounds, Compositions And Methods To Make And UseUSPTOApplication 14068450
- PendingForms Of R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE Dihydrogen PhosphateUSPTOApplication 13867951
- PendingTherapeutic Combination Of Daptomycin And Protein Synthesis Inhibitor Antibiotic, And Methods Of UseUSPTOApplication 13911990
Show all 13 patent records
- Oxazolidinone Containing Dimer Compounds, Compositions And Methods To Make And UseFeb 27, 2014 · Application 14068450Pending
- Forms Of R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE Dihydrogen PhosphateNov 21, 2013 · Application 13867951Pending
- Therapeutic Combination Of Daptomycin And Protein Synthesis Inhibitor Antibiotic, And Methods Of UseOct 17, 2013 · Application 13911990Pending
- Therapeutic Combination Of Daptomycin And Protein Synthesis Inhibitor Antibiotic, And Methods Of UseJun 11, 2013 · US 8,461,188Granted
- Dihydrofolate Reductase InhibitorsApplication PCTUS2011038871Pending
- Gyrase InhibitorsApplication PCTUS2010048538Pending
- Oxazolidinone Containing Dimer Compounds, Compositions And Methods To Make And UseApplication PCTUS2010036283Pending
- Methods For Preparing Oxazolidinones And Compositions Containing ThemApplication PCTUS2009060267Pending
- Methods Of Treating Subjects With Renal Impairment Using TedizolidApplication PCTUS2014059488Pending
- Antimicrobial Compounds And Methods Of UseApplication PCTUS2008053346Pending
- Methods Of Treating Subjects With Renal Impairment Using TedizolidApplication 61887571Pending
- Tricyclic Gyrase InhibitorsApplication 61876688Pending
- Therapeutic Combination Of Daptomycin And Protein Synthesis Inhibitor Antibiotic, And Methods Of UseApplication PCTUS2012061048Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .